This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
by Zacks Equity Research
Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.
Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout
by Zacks Equity Research
Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.
Amgen (AMGN) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
by Zacks Equity Research
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Medicare's First Price Negotiation List Targets Expensive Drugs
by Kinjel Shah
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.
Top Stock Reports for Alphabet, Roche & Honeywell International
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Roche Holding AG (RHHBY) and Honeywell International Inc. (HON).
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
by Zacks Equity Research
The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Beat the Market Like Zacks: Hubbell, Adobe, Nikola in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
by Zacks Equity Research
AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Beat the Market the Zacks Way: Caterpillar, Amgen, Broadridge Financial Solutions in Focus
by Santanu Roy
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
by Zacks Equity Research
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.
Company News for Aug 7, 2023
by Zacks Equity Research
Companies in The News Are: PPL,PAA,TU,AMGN
Ligand (LGND) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.